AAIC–live in Denver and virtually–will close out month.

Lynne Peterson is the Senior Writer for Trends-in-Medicine.

Here is the medical news to watch for July 26-August 1, 2021.

Cardiology: Part 2 of the Heart Rhythm Society (HRS) annual meeting will be hybrid, taking place both in person in Boston and virtually July 28-31.

Neurology: The Alzheimer’s Association International Conference (AAIC, formerly ICAD) will take place July 26-30, both in person in Denver and virtually. The controversial approval of Biogen’s Aduhelm (aducanumab) for Alzheimer’s disease is likely to be a hot topic, but the data to watch include:

  • Additional data from the open-label Phase IIa INFRONT-2 trial of Alector’s AL-001, an anti-SORT1, in frontotemporal dementia.
  • A Phase Ib study of AC Immune’s ACI-24, an anti-amyloid beta vaccine for Alzheimer’s disease-like characteristics in Down’s syndrome patients.
  • A Phase I trial of Athira Pharma’s ATH-1017, an HGF/MET promoter, in mild-to-moderate Alzheimer’s disease.
  • Safety and cognition results for the first 50 patients who completed nine months of treatment with an oral agent that binds misfolded filamin A in the brain—Cassava Sciences’ simufilam (PTI-125)—from a Phase IIb trial in Alzheimer’s disease.


  • The FDA is hosting a webinar on July 29 on its final guidance on non-clinical testing and clinical consideration in development of implanted brain-computer interface (BCI) devices for patients with paralysis or amputation.
  • The FDA’s Oncology Center of Excellence is holding a webinar on July 29 on advancing equity in Asian American and Pacific islander communities, including discussions of disparities in cancer care and false blame for spreading Covid-19.

Lynne Peterson, Contributing Writer, Senior Writer for Trends-in-Medicine

Cat ID: 270

Topic ID: 74,270,730,270,33,361,817,192,150,151,925,269,816